CompletedPhase 3NCT01215747

Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis

Studying AA amyloidosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
C.T. Development America, Inc.
Principal Investigator
Tomasz Sablinski, MD, PhD
CT Development America, Inc.
Intervention
KIACTA (eprodisate disodium)(drug)
Enrollment
261 enrolled
Eligibility
18-80 years · All sexes
Timeline
20102016

Study locations (30)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01215747 on ClinicalTrials.gov

Other trials for AA amyloidosis

Additional recruiting or active studies for the same condition.

See all trials for AA amyloidosis

← Back to all trials